Based within Oxfordshire’s biotechnology hub, we are using our expertise in growing and modifying clostridia, combined with an extensive proprietary technology portfolio, to push new boundaries in protein expression. With an emphasis on sustainable technologies, we are adapting features of this exciting new host to increase the availability of previously difficult-to-express proteins and biocatalysts from Life Science applications to Agri-Tech.
Biocleave were the first to use endogenous CRISPR-cas for genome editing in clostridia and we have over 15 years’ experience in engineering, adapting and fermenting these microbes. The team comprises experts in molecular biology, protein biochemistry, fermentation and enzyme chemistry, who are utilizing this microbe’s unique characteristics to overcome the typical protein expression challenges of production host toxicity and costly development cycles. Our goal is to ensure availability of previously unobtainable reagents to support and expand avenues of vital life science research.
